Onco-Innovations Advances Manufacturing Scale-Up for Lead Cancer Drug Candidate ONC010
Onco-Innovations Limited reports progress in intermediate-scale manufacturing for its nanoparticle-formulated oncology candidate ONC010, moving it closer to clinical trials in Australia.
Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) announced continued progress in intermediate-scale manufacturing and process development for key precursor components of ONC010, its lead nanoparticle-formulated oncology candidate. The company is advancing the candidate through IND-enabling development, with manufacturing activities conducted in partnership with Dalton Pharma Services as part of Onco's integrated chemistry, manufacturing and controls strategy.
The work focuses on process optimization, analytical characterization and manufacturing reproducibility to support future GMP production, regulatory readiness and planned first-in-human clinical development activities in Australia. This milestone is significant because it moves ONC010 closer to clinical trials, a critical step in bringing potential new cancer treatments to patients.
Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. The company's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. It has secured an exclusive worldwide license to patented technology that targets solid tumours.
The advancement of ONC010's manufacturing scale-up is important for several reasons. First, it demonstrates progress in the company's pipeline, potentially increasing investor confidence. Second, successful scale-up is essential for producing sufficient quantities of the drug for clinical trials and, eventually, commercial use. Third, the focus on process optimization and reproducibility helps ensure that the final product meets regulatory standards for safety and efficacy.
The planned first-in-human clinical trials in Australia represent a key regulatory pathway for Onco-Innovations. Australia offers a streamlined clinical trial approval process, which can accelerate the timeline to initial human testing. If successful, ONC010 could offer a new treatment option for patients with solid tumours, addressing a significant unmet medical need.
For more information about Onco-Innovations, visit https://oncoinnovations.com/. The full press release is available at https://ibn.fm/Unt8n.